PMID- 16606863
OWN - NLM
STAT- MEDLINE
DCOM- 20061020
LR  - 20211020
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Print)
IS  - 1355-6037 (Linking)
VI  - 92
IP  - 10
DP  - 2006 Oct
TI  - Beneficial effects of abciximab in patients with primary percutaneous 
      intervention for acute ST segment elevation myocardial infarction in clinical 
      practice.
PG  - 1484-9
AB  - OBJECTIVES: To assess the safety and effectiveness of abciximab in patients with 
      ST elevation myocardial infarction (STEMI) treated with primary percutaneous 
      coronary intervention (PCI) in clinical practice. METHODS: Data were analysed of 
      2184 consecutive patients treated with primary PCI for acute STEMI and either 
      concomitant abciximab or no glycoprotein IIb/IIIa inhibitor (control group), who 
      were prospectively enrolled in the Acute Coronary Syndromes (ACOS) registry 
      between July 2000 and November 2002. RESULTS: Patients who were treated with 
      abciximab were younger than the control group, and fewer of them had a history of 
      stroke/transient ischaemic attack and systemic hypertension, but more of them had 
      three-vessel coronary artery disease and cardiogenic shock. Cumulated mid-term 
      survival for patients treated with abciximab was significantly higher than in the 
      control group (91% v 79%, log rank p < 0.05, median observational time 375 days, 
      range 12-34 months). The Cox proportional hazards model of mid-term mortality 
      after admission with adjustment for baseline characteristics showed that 
      mortality was significantly lower in the abciximab group than in the control 
      group (hazard ratio 0.68, 95% confidence interval 0.49 to 0.95). Whereas overall 
      there was no difference in bleeding complications, patients older than 75 years 
      had more major bleeding events with abciximab (12.5% v 3.4%, p = 0.03). 
      CONCLUSION: In clinical practice adjunctive treatment with abciximab in patients 
      with primary PCI for acute STEMI was associated with a reduction in mid-term 
      mortality. The subgroup of patients older than 75 years who were treated with 
      abciximab had more major bleeding complications.
FAU - Heer, T
AU  - Heer T
AD  - Department of Cardiology, Herzzentrum Ludwigshafen, Ludwigshafen, Germany. 
      heert@klilu.de
FAU - Zeymer, U
AU  - Zeymer U
FAU - Juenger, C
AU  - Juenger C
FAU - Gitt, A K
AU  - Gitt AK
FAU - Wienbergen, H
AU  - Wienbergen H
FAU - Zahn, R
AU  - Zahn R
FAU - Gottwik, M
AU  - Gottwik M
FAU - Senges, J
AU  - Senges J
CN  - Acute Coronary Syndromes Registry Investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20060410
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Anticoagulants)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/methods/mortality
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Anticoagulants/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immunoglobulin Fab Fragments/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/mortality/*therapy
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
PMC - PMC1861035
EDAT- 2006/04/12 09:00
MHDA- 2006/10/21 09:00
PMCR- 2009/10/01
CRDT- 2006/04/12 09:00
PHST- 2006/04/12 09:00 [pubmed]
PHST- 2006/10/21 09:00 [medline]
PHST- 2006/04/12 09:00 [entrez]
PHST- 2009/10/01 00:00 [pmc-release]
AID - hrt.2005.085456 [pii]
AID - ht85456 [pii]
AID - 10.1136/hrt.2005.085456 [doi]
PST - ppublish
SO  - Heart. 2006 Oct;92(10):1484-9. doi: 10.1136/hrt.2005.085456. Epub 2006 Apr 10.